Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review

• Published in: Acta otorhino-laryngologica italica Vol. 42; no. 6; pp. 545 - 553
• Main Authors: Turri-Zanoni, Mario, Dalfino, Gianluca, Lechner, Matt, Dallan, Iacopo, Battaglia, Paolo, Facco, Carla, Franzi, Francesca, Gravante, Giacomo, Ferrari, Marco, Terzakis, Dimitrios, Jay, Amrita, Forster, Martin D, Ambrosoli, Andrea Luigi, Bignami, Maurizio, Georgalas, Christos, Herman, Philippe, Nicolai, Piero, Lund, Valerie J, Castelnuovo, Paolo
• Format: Journal Article
• Language: English
• Published: Italy Pacini Editore Srl 01-12-2022
• Subjects: Disease-Free Survival; Humans; Multicenter Studies as Topic; Paranasal Sinus Neoplasms - surgery; Retrospective Studies; Rhinology; Sarcoma - pathology; endoscopic endonasal surgery; biphenotypic sarcoma; anterior skull base; sinonasal cancer; low-grade sarcoma
• ISSN: 1827-675X; 0392-100X; 1827-675X
• DOI: 10.14639/0392-100X-N2087

Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm.
Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines.
A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively.
BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.